Inalacor

Fluticasone Propionate, the active ingredient in Inalacor, is a corticosteroid presented as an inhalation product for inhalation use. It is employed to reduce airway inflammation in patients with asthma and chronic obstructive pulmonary disease. It is indicated for long‑term maintenance therapy and is delivered via a metered‑dose inhaler designed to ensure consistent particle size.

GNH USA supplies Inalacor as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions.

Inalacor, an inhaled corticosteroid, is used to manage inflammatory airway diseases. - Asthma: reduces airway inflammation, improves symptom control and decreases frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): decreases airway inflammation, helps reduce exacerbation risk and improves lung function. - Chronic bronchitis (as part of COPD): controls inflammatory processes in the bronchial mucosa, aiding symptom relief. - Exercise‑induced bronchoconstriction: provides prophylactic anti‑inflammatory effect to prevent airway narrowing during physical activity.

Inhaled fluticasone propionate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Oral thrush (candidiasis): fungal infection of the mouth and throat. - Hoarseness or dysphonia: voice changes due to local irritation. - Cough or throat irritation: discomfort after inhalation.

Serious or Rare Side Effects: - Adrenal suppression: reduced endogenous cortisol production. - Pneumonia: especially in patients with COPD. - Paradoxical bronchospasm: sudden worsening of airway obstruction.

When prescribing Inalacor, several precautionary measures should be observed to minimize risk and ensure optimal therapy. - Assess inhaler technique: verify patient can use the device correctly. - Monitor for oral candidiasis: advise rinsing mouth after each use. - Evaluate for active tuberculosis: avoid use in uncontrolled TB infection. - Use lowest effective dose: limit systemic exposure. - Avoid in patients with known hypersensitivity to fluticasone or excipients. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Fluticasone propionate can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure and risk of adrenal suppression. - Systemic glucocorticoids (e.g., oral prednisone): additive immunosuppressive effects and heightened adrenal suppression.

Moderate Interactions (Monitor Closely): - Ritonavir (HIV protease inhibitor): moderate increase in fluticasone levels. - Diuretics (e.g., furosemide): may enhance fluid retention when combined with corticosteroids. - β2‑agonists (e.g., albuterol): possible additive bronchodilator effect; monitor for tachycardia.